Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPN14770 in Male Adolescents With Fragile X Syndrome
NCT05163808Phase 3Completed
- Sponsor
- Tetra Therapeutics
- Start
- Mar 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zatolmilast in Fragile X syndrome (FXS) (2 arms), sponsored by Tetra Therapeutics. Primary endpoint: NIH Toolbox Cognitive Battery cognition crystallized composite score at 13 weeks. Started Mar 2022; status: completed.
02
Drugs
zatolmilast
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT05163808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163808.